MX348361B - Formulaciones resistentes al abuso. - Google Patents

Formulaciones resistentes al abuso.

Info

Publication number
MX348361B
MX348361B MX2012006829A MX2012006829A MX348361B MX 348361 B MX348361 B MX 348361B MX 2012006829 A MX2012006829 A MX 2012006829A MX 2012006829 A MX2012006829 A MX 2012006829A MX 348361 B MX348361 B MX 348361B
Authority
MX
Mexico
Prior art keywords
dosage form
abuse
hydromorphone
resistant formulations
sustained
Prior art date
Application number
MX2012006829A
Other languages
English (en)
Other versions
MX2012006829A (es
Inventor
Hamed Ehab
A Vega Zepeda Manuel
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of MX2012006829A publication Critical patent/MX2012006829A/es
Publication of MX348361B publication Critical patent/MX348361B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta revelación se refiere a una forma farmacéutica oral de liberación sostenida para la administración de una vez al día que comprende una matriz que contiene un modificador de la viscosidad y gránulos revestidos que contienen hidromorfona. La forma farmacéutica puede tener un perfil de liberación de modo tal que 16 horas después de la administración, se libera menos de alrededor de 85 por ciento de la hidromorfona. Además, la forma farmacéutica puede tener resistencia al alcohol y/o a la trituración.
MX2012006829A 2009-12-17 2010-12-16 Formulaciones resistentes al abuso. MX348361B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28751509P 2009-12-17 2009-12-17
PCT/US2010/060755 WO2011084593A2 (en) 2009-12-17 2010-12-16 Abuse-resistant formulations

Publications (2)

Publication Number Publication Date
MX2012006829A MX2012006829A (es) 2012-07-10
MX348361B true MX348361B (es) 2017-06-07

Family

ID=43618139

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006829A MX348361B (es) 2009-12-17 2010-12-16 Formulaciones resistentes al abuso.

Country Status (10)

Country Link
US (2) US20120225122A1 (es)
EP (1) EP2512456A2 (es)
JP (1) JP5894717B2 (es)
CN (1) CN102665694A (es)
AU (1) AU2010339882B2 (es)
CA (1) CA2784407A1 (es)
IL (1) IL219961A (es)
MX (1) MX348361B (es)
NZ (1) NZ600640A (es)
WO (1) WO2011084593A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784336B2 (en) 2005-08-24 2014-07-22 C. R. Bard, Inc. Stylet apparatuses and methods of manufacture
US8388546B2 (en) 2006-10-23 2013-03-05 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US7794407B2 (en) 2006-10-23 2010-09-14 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
ES2557084T3 (es) 2007-11-26 2016-01-21 C. R. Bard, Inc. Sistema integrado para la colocación intravascular de un catéter
US8781555B2 (en) 2007-11-26 2014-07-15 C. R. Bard, Inc. System for placement of a catheter including a signal-generating stylet
US10524691B2 (en) 2007-11-26 2020-01-07 C. R. Bard, Inc. Needle assembly including an aligned magnetic element
US10449330B2 (en) 2007-11-26 2019-10-22 C. R. Bard, Inc. Magnetic element-equipped needle assemblies
US9521961B2 (en) 2007-11-26 2016-12-20 C. R. Bard, Inc. Systems and methods for guiding a medical instrument
US10751509B2 (en) 2007-11-26 2020-08-25 C. R. Bard, Inc. Iconic representations for guidance of an indwelling medical device
US8849382B2 (en) 2007-11-26 2014-09-30 C. R. Bard, Inc. Apparatus and display methods relating to intravascular placement of a catheter
US9649048B2 (en) 2007-11-26 2017-05-16 C. R. Bard, Inc. Systems and methods for breaching a sterile field for intravascular placement of a catheter
US8478382B2 (en) 2008-02-11 2013-07-02 C. R. Bard, Inc. Systems and methods for positioning a catheter
US9901714B2 (en) 2008-08-22 2018-02-27 C. R. Bard, Inc. Catheter assembly including ECG sensor and magnetic assemblies
US8437833B2 (en) 2008-10-07 2013-05-07 Bard Access Systems, Inc. Percutaneous magnetic gastrostomy
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
ES2745861T3 (es) 2009-06-12 2020-03-03 Bard Access Systems Inc Aparato, algoritmo de procesamiento de datos asistido por ordenador y medio de almacenamiento informático para posicionar un dispositivo endovascular en o cerca del corazón
US9445734B2 (en) 2009-06-12 2016-09-20 Bard Access Systems, Inc. Devices and methods for endovascular electrography
US9532724B2 (en) 2009-06-12 2017-01-03 Bard Access Systems, Inc. Apparatus and method for catheter navigation using endovascular energy mapping
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
EP2517622A3 (en) 2009-09-29 2013-04-24 C. R. Bard, Inc. Stylets for use with apparatus for intravascular placement of a catheter
WO2011044421A1 (en) 2009-10-08 2011-04-14 C. R. Bard, Inc. Spacers for use with an ultrasound probe
ES2811107T3 (es) 2010-02-02 2021-03-10 Bard Inc C R Aparato y método para conducción de catéter y localización de punta
EP2912999B1 (en) 2010-05-28 2022-06-29 C. R. Bard, Inc. Apparatus for use with needle insertion guidance system
EP2913000B1 (en) 2010-05-28 2020-02-12 C.R. Bard, Inc. Apparatus for use with needle insertion guidance system
CA2806353A1 (en) 2010-08-09 2012-02-16 C.R. Bard Inc. Support and cover structures for an ultrasound probe head
CN103442632A (zh) 2010-08-20 2013-12-11 C·R·巴德股份有限公司 Ecg辅助导管末端放置的再确认
CN103189009B (zh) 2010-10-29 2016-09-07 C·R·巴德股份有限公司 医疗设备的生物阻抗辅助放置
AU2012278809B2 (en) 2011-07-06 2016-09-29 C.R. Bard, Inc. Needle length determination and calibration for insertion guidance system
USD699359S1 (en) 2011-08-09 2014-02-11 C. R. Bard, Inc. Ultrasound probe head
WO2013070775A1 (en) 2011-11-07 2013-05-16 C.R. Bard, Inc Ruggedized ultrasound hydrogel insert
WO2013158638A1 (en) * 2012-04-17 2013-10-24 Mylan, Inc. Stable dosage forms of skeletal muscle relaxants with extended release coating
US10820885B2 (en) 2012-06-15 2020-11-03 C. R. Bard, Inc. Apparatus and methods for detection of a removable cap on an ultrasound probe
ES2706994T3 (es) * 2012-09-03 2019-04-02 Daiichi Sankyo Co Ltd Composición farmacéutica de liberación prolongada de administración oral que contiene clorhidrato de hidromorfona
CA2817728A1 (en) * 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
ES2811323T3 (es) 2014-02-06 2021-03-11 Bard Inc C R Sistemas para el guiado y la colocación de un dispositivo intravascular
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10973584B2 (en) 2015-01-19 2021-04-13 Bard Access Systems, Inc. Device and method for vascular access
US10349890B2 (en) 2015-06-26 2019-07-16 C. R. Bard, Inc. Connector interface for ECG-based catheter positioning system
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US11000207B2 (en) 2016-01-29 2021-05-11 C. R. Bard, Inc. Multiple coil system for tracking a medical device
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2020081373A1 (en) 2018-10-16 2020-04-23 Bard Access Systems, Inc. Safety-equipped connection systems and methods thereof for establishing electrical connections
US11986460B2 (en) 2018-11-26 2024-05-21 The Procter & Gamble Company Solid pharmaceutical preparation containing lipoic acid and use thereof
EP4062973A4 (en) 2019-11-20 2023-11-29 Shionogi & Co., Ltd SOLID FORMULATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYL MORPHINAND DERIVATIVE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
EP1765303B2 (de) * 2004-07-01 2022-11-23 Grünenthal GmbH Gegen missbrauch gesicherte, oral tablette
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
PL2200593T3 (pl) * 2007-09-13 2017-02-28 Cima Labs Inc. Preparat leku odporny na nadużywanie
ES2337935T3 (es) * 2007-11-09 2010-04-30 Acino Pharma Ag Comprimidos de accion retardada con hidromorfona.
EP2568977A1 (en) * 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms

Also Published As

Publication number Publication date
WO2011084593A2 (en) 2011-07-14
WO2011084593A3 (en) 2012-03-29
IL219961A (en) 2017-06-29
MX2012006829A (es) 2012-07-10
US9474721B2 (en) 2016-10-25
CN102665694A (zh) 2012-09-12
NZ600640A (en) 2014-11-28
IL219961A0 (en) 2012-07-31
JP5894717B2 (ja) 2016-03-30
JP2013514386A (ja) 2013-04-25
AU2010339882A1 (en) 2012-07-05
AU2010339882B2 (en) 2016-10-27
EP2512456A2 (en) 2012-10-24
US20120225122A1 (en) 2012-09-06
US20140294953A1 (en) 2014-10-02
CA2784407A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
NZ600640A (en) Abuse-resistant formulations
MX347753B (es) Formulaciones resistentes al abuso.
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
WO2008135527A3 (en) Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
MX2012013021A (es) Formulaciones resistentes a alcohol.
MX2007009162A (es) Formas de dosis rsistente al alcohol.
NZ610701A (en) Once daily formulation of lacosamide
MX2023008408A (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
MX343358B (es) Tabletas de acetato de ulipristal.
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
TW200621317A (en) Pharmaceutical composition
MY156332A (en) Quinuclidine carbonate derivatives and medicinal composition thereof
MX2009004439A (es) Composicion de ibuprofeno.
WO2011104652A3 (en) Veterinary compositions
UA103179C2 (ru) Фармацевтическая композиция, которая содержит эзетимиб
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012052169A3 (de) Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
MX2012013023A (es) Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.
WO2009019662A3 (en) Oral metaxalone compositions
GB2495563A (en) Co-processed excipient compositions
WO2009069151A3 (en) Controlled release composition

Legal Events

Date Code Title Description
FG Grant or registration